{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:32:53Z","timestamp":1791073973393,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ncl.2025.08.011","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:27:04Z","timestamp":1760567224000},"page":"23-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Placebo Response in Acute and Prophylactic Treatment of Migraine"],"prefix":"10.1016","volume":"44","author":[{"given":"N.R.A.","family":"Bruijn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Huessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fronczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Diener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Al-Hassany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Lifting the Burden: the Global Campaign against H. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"Suppl 7","key":"10.1016\/j.ncl.2025.08.011_bib4","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society","volume":"8","year":"1988","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11916-010-0165-z","article-title":"Mechanism of chronic migraine","volume":"15","author":"Aurora","year":"2011","journal-title":"Curr Pain Headache Rep"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.011_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"10283","key":"10.1016\/j.ncl.2025.08.011_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","article-title":"Migraine: integrated approaches to clinical management and emerging treatments","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"issue":"Pt 1","key":"10.1016\/j.ncl.2025.08.011_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/123.1.9","article-title":"Ergotamine in the acute treatment of migraine: a review and European consensus","volume":"123","author":"Tfelt-Hansen","year":"2000","journal-title":"Brain"},{"issue":"3 Pt 1","key":"10.1016\/j.ncl.2025.08.011_bib9","first-page":"585","article-title":"Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"45","year":"1995","journal-title":"Neurology"},{"issue":"9294","key":"10.1016\/j.ncl.2025.08.011_bib10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","article-title":"The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis","volume":"24","author":"Lampl","year":"2023","journal-title":"J Headache Pain"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.011_bib12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1526-4610.2008.01098.x","article-title":"Prophylaxis: headaches that never happen","volume":"48","author":"Loder","year":"2008","journal-title":"Headache"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.011_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","article-title":"Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions","volume":"21","author":"Al-Hassany","year":"2022","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.011_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1468-2982.2000.00117.x","article-title":"Guidelines for controlled trials of drugs in migraine: second edition","volume":"20","author":"Tfelt-Hansen","year":"2000","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0333102411417901","article-title":"Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators","volume":"32","author":"Tfelt-Hansen","year":"2012","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.011_bib16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.011_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00228-005-0088-5","article-title":"A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials","volume":"62","author":"Macedo","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejpain.2007.03.002","article-title":"Placebo response in the prophylaxis of migraine: a meta-analysis","volume":"12","author":"Macedo","year":"2008","journal-title":"Eur J Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-2982.1991.1101001.x","article-title":"Guidelines for controlled trials of drugs in migraine. First edition. International headache society committee on clinical trials in migraine","volume":"11","year":"1991","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2025.08.011_bib21","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.ncl.2025.08.011_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ncl.2025.08.011_bib23","unstructured":"Higgins JPT, Li T, Deeks JJ, Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023], Section 6.5.2. In: Higgins JPT, Thomas J, Chandler J, et al., Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available at: cochrane.org\/handbook."},{"issue":"2","key":"10.1016\/j.ncl.2025.08.011_bib24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3758\/s13428-012-0261-6","article-title":"Three-level meta-analysis of dependent effect sizes","volume":"45","author":"Van den Noortgate","year":"2013","journal-title":"Behav Res Methods"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000783","article-title":"To adjust or not to adjust: it is not the tests performed that count, but how they are reported and interpreted","volume":"3","author":"Boulesteix","year":"2024","journal-title":"BMJ Med"},{"key":"10.1016\/j.ncl.2025.08.011_bib26","series-title":"R: a language and environment for statistical computing","year":"2025"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1526-4610.2002.02009.x","article-title":"Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials","volume":"42","author":"Dodick","year":"2002","journal-title":"Headache"},{"issue":"10","key":"10.1016\/j.ncl.2025.08.011_bib28","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4065\/78.10.1214","article-title":"Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies","volume":"78","author":"Winner","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.011_bib29","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/WNL.49.5.1225","article-title":"Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies","volume":"49","author":"Ryan","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.011_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.clinthera.2005.04.003","article-title":"Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating\/rapid-release formulation of sumatriptan tablets","volume":"27","author":"Sheftell","year":"2005","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.011_bib31","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1526-4610.2006.00466.x","article-title":"Efficacy of Rizatriptan 10 mg administered early in a migraine attack","volume":"46","author":"Cady","year":"2006","journal-title":"Headache"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.011_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","article-title":"Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan","volume":"28","author":"Goadsby","year":"2008","journal-title":"Cephalalgia"},{"issue":"11","key":"10.1016\/j.ncl.2025.08.011_bib33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","article-title":"Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study","volume":"14","author":"Bigal","year":"2015","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.011_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.clinthera.2006.03.013","article-title":"A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults","volume":"28","author":"Wendt","year":"2006","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-018-0881-z","article-title":"Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study","volume":"19","author":"Landy","year":"2018","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2025.08.011_bib36","first-page":"9","article-title":"The international classification of headache disorders: 2nd edition","volume":"24","year":"2004","journal-title":"Cephalalgia"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.011_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1468-2982.2004.00817.x","article-title":"Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls","volume":"25","author":"Loder","year":"2005","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.011_bib38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJM199108013250504","article-title":"Treatment of migraine attacks with sumatriptan","volume":"325","author":"Subcutaneous Sumatriptan International","year":"1991","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ncl.2025.08.011_bib39","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.1991.03460210077033","article-title":"Treatment of acute migraine with subcutaneous sumatriptan","volume":"265","author":"Cady","year":"1991","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ncl.2025.08.011_bib40","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1212\/WNL.44.9.1587","article-title":"Subcutaneous sumatriptan during the migraine aura. Sumatriptan aura study group","volume":"44","author":"Bates","year":"1994","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.011_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000116760","article-title":"Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group","volume":"31","year":"1991","journal-title":"Eur Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2025.08.011_bib42","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1046\/j.1468-2982.1992.1205308.x","article-title":"Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group","volume":"12","author":"Visser","year":"1992","journal-title":"Cephalalgia"},{"issue":"6","key":"10.1016\/j.ncl.2025.08.011_bib43","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0029-7844(95)00288-3","article-title":"The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group","volume":"86","author":"Facchinetti","year":"1995","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.011_bib44","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s004150050560","article-title":"Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos","volume":"247","author":"de Craen","year":"2000","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.011_bib45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"issue":"7","key":"10.1016\/j.ncl.2025.08.011_bib46","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.011_bib47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/j.pain.0000000000002365","article-title":"Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis","volume":"163","author":"Swerts","year":"2022","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib48","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1080\/13696998.2023.2248842","article-title":"Meta-regression to explain the placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention","volume":"26","author":"Regnier","year":"2023","journal-title":"J Med Econ"},{"issue":"9715","key":"10.1016\/j.ncl.2025.08.011_bib49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(09)61706-2","article-title":"Biological, clinical, and ethical advances of placebo effects","volume":"375","author":"Finniss","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib50","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/13696998.2024.2323900","article-title":"Placebo responses vary by route of administration in migraine prevention trials. What does this mean?","volume":"27","author":"Deligianni","year":"2024","journal-title":"J Med Econ"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.011_bib51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1468-2982.2008.01752.x","article-title":"Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies","volume":"29","author":"Evers","year":"2009","journal-title":"Cephalalgia"},{"issue":"4","key":"10.1016\/j.ncl.2025.08.011_bib52","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jpeds.2014.06.040","article-title":"Harnessing the placebo effect in pediatric migraine clinic","volume":"165","author":"Faria","year":"2014","journal-title":"J Pediatr"},{"issue":"7_Supplement_1","key":"10.1016\/j.ncl.2025.08.011_bib53","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1212\/WNL.0000000000211143","article-title":"Efficacy and safety of fremanezumab for the preventive treatment of episodic migraine in children and adolescents: a phase 3, randomized, double-blind, placebo-controlled study (PL5.001)","volume":"104","author":"Hershey","year":"2025","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2025.08.011_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050166","article-title":"Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy","volume":"5","author":"Rheims","year":"2008","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/pr.2013.66","article-title":"Placebo effects in children: a review","volume":"74","author":"Weimer","year":"2013","journal-title":"Pediatr Res"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.011_bib56","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1097\/j.pain.0000000000002341","article-title":"The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis","volume":"163","author":"Schmidt","year":"2022","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1353\/ken.2016.0004","article-title":"Placebo effects and the ethics of therapeutic communication: a pragmatic perspective","volume":"26","author":"Annoni","year":"2016","journal-title":"Kennedy Inst Ethics J"},{"issue":"3","key":"10.1016\/j.ncl.2025.08.011_bib58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/brainsci15030280","article-title":"Current trends in pediatric migraine: clinical insights and therapeutic strategies","volume":"15","author":"Khan","year":"2025","journal-title":"Brain Sci"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2025.08.011_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000085038","article-title":"Defining response in migraine: which endpoints are important?","volume":"53","author":"Edmeads","year":"2005","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2025.08.011_bib60","doi-asserted-by":"crossref","DOI":"10.1177\/25158163221120103","article-title":"Placebo response with subcutaneous injections in calcitonin gene-related peptide receptor monoclonal antibody migraine preventative trials \u2013 a systematic review and meta-analysis","volume":"5","author":"Gorantla","year":"2022","journal-title":"Cephalalgia Reports"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s13063-021-05454-8","article-title":"Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects","volume":"22","author":"Hafli\u00f0ad\u00f3ttir","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.ncl.2025.08.011_bib62","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.ncl.2025.08.011_bib63","unstructured":"Deeks JJ, Higgins JPT, Altman DG, et al., Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024], Section 10.10. In: Higgins JPT, Thomas J, Chandler J, et al., Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available at: cochrane.org\/handbook."},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-020-01178-3","article-title":"European Headache Federation recommendations for placebo and nocebo terminology","volume":"21","author":"Mitsikostas","year":"2020","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1016\/j.ncl.2025.08.011_bib65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10194-023-01587-0","article-title":"The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression","volume":"24","author":"Tepper","year":"2023","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.ncl.2025.08.011_bib66","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/0333102420960020","article-title":"The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: a systematic review of clinical trials of preventative pharmacological migraine treatments","volume":"41","author":"Evans","year":"2021","journal-title":"Cephalalgia"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861925000684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:08:27Z","timestamp":1773047307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861925000684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0733861925000684"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.011","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo Response in Acute and Prophylactic Treatment of Migraine","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2025.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}